The Pharmaceutical Services Negotiating Committee (PSNC) has reported that there are currently issues with the supply of Evotrox® (levothyroxine) suspension. The supply problems relate to the 25mcg/5ml and 50mcg/5ml strengths of Evotrox oral solution. The company has confirmed that the 100mcg/5ml oral solution has been withdrawn. Please see link below for further information.